Sona Nanotech Inc. (SNANF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $27.7M is the value of all shares combined. Beta 0.67: the stock has moved about 33% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSona Nanotech Inc. (SNANF) trades at $0.242. Sona Nanotech Inc. is a nanotechnology life sciences company focused on developing and manufacturing gold nanorod products for diagnostic and therapeutic applications. Market cap: $27.7M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SNANF: SNANF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SNANF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
SNANF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Sona Nanotech Inc. (SNANF) Healthcare & Pipeline Overview
Sona Nanotech Inc. develops and manufactures gold nanorod-based products for diagnostic and therapeutic applications, including its Nanotech COVID-19 Lateral Flow Assay. With a market capitalization of $27.7M, the company targets medical, consumer, military, and veterinary diagnostics markets, positioning itself within the growing nanotechnology-driven healthcare sector.
What Is the Investment Thesis for SNANF?
Sona Nanotech Inc. presents a speculative investment opportunity within the nanotechnology-driven healthcare sector. The company's focus on gold nanorod technology for diagnostics and therapeutics offers potential for growth, particularly with its Nanotech COVID-19 Lateral Flow Assay. However, the company's negative P/E ratio of -11.46 indicates it is not currently profitable. Key value drivers include successful commercialization of its diagnostic products and expansion into new therapeutic applications. Growth catalysts involve securing regulatory approvals and establishing strategic partnerships. Potential risks include competition from established players in the diagnostics market and the company's ability to secure additional funding. Investors should carefully consider the company's financial position and the inherent risks associated with early-stage nanotechnology companies.
Based on FMP financials and quantitative analysis
SNANF Key Highlights
Market capitalization of $27.7M, reflecting its small-cap status within the healthcare sector.
- Negative P/E ratio of -11.46, indicating the company is currently unprofitable.
- Beta of 0.67, suggesting lower volatility compared to the overall market.
- Focus on gold nanorod technology, offering potential for innovation in diagnostics and therapeutics.
- Development of the Nanotech COVID-19 Lateral Flow Assay, targeting the demand for rapid COVID-19 testing.
Who Are SNANF's Competitors?
SNANF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ACHFF Arch Biopartners Inc. | $0.62 | -10.10% | $42.4M | — |
| AIRDF Rocket Doctor AI Inc. | $0.42 | -0.02% | $40.7M | — |
| CLTEF Calliditas Therapeutics Ab | $0.18 | 0.00% | $10.5M | — |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ETST Earth Science Tech, Inc. | $0.09 | -1.53% | $25.9M | — |
| BIOQ Bioqual, Inc. | $33.00 | 0.00% | $29.5M | 389-signal |
| QUCY QUCY | $1.34 | -1.82% | $30.6M | — |
| MDXH MDxHealth SA | $0.68 | -2.31% | $34.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are SNANF's Key Strengths?
Proprietary gold nanorod technology platform.
- Development of the Nanotech COVID-19 Lateral Flow Assay.
- Expertise in nanotechnology applications in diagnostics and therapeutics.
- Potential for expansion into new therapeutic areas.
What Are SNANF's Weaknesses?
Small market capitalization and limited financial resources.
- Negative P/E ratio indicating lack of profitability.
- Dependence on a limited number of products and services.
- OTC market listing, potentially limiting investor access.
What Could Drive SNANF Stock Higher?
Potential regulatory approvals for its Nanotech COVID-19 Lateral Flow Assay in new markets.
- Expansion of its product portfolio with new diagnostic assays.
- Strategic partnerships with pharmaceutical companies for therapeutic applications.
- Increased adoption of its gold nanorod technology in various industries.
- Publication of research and clinical data supporting the efficacy of its products.
What Are the Key Risks for SNANF?
Financial-distress signal — its Altman Z-Score of -46.18 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established diagnostic companies with greater resources.
- Regulatory hurdles and approval processes for its products.
- Fluctuations in the price of gold, impacting its manufacturing costs.
- Limited financial resources and dependence on additional funding.
- Technological obsolescence and the emergence of alternative diagnostic technologies.
What Are the Growth Opportunities for SNANF?
- Expansion into new therapeutic areas: Sona Nanotech can leverage its gold nanorod technology to develop targeted therapies for cancer and other diseases. The market for targeted drug delivery is projected to reach $100 billion by 2030, offering significant growth potential. The company's competitive advantage lies in its expertise in gold nanorod synthesis and functionalization, enabling the development of highly specific and effective therapies.
- Strategic partnerships with pharmaceutical companies: Collaborating with pharmaceutical companies can accelerate the development and commercialization of Sona Nanotech's therapeutic products. The pharmaceutical industry is increasingly seeking innovative drug delivery technologies, creating opportunities for partnerships. A successful partnership could provide Sona Nanotech with funding, expertise, and access to established distribution channels.
- Geographic expansion into new markets: Sona Nanotech can expand its sales and marketing efforts into new geographic regions, particularly in Asia and Europe, where there is growing demand for advanced diagnostic and therapeutic solutions. The global diagnostics market is expected to reach $150 billion by 2028, with significant growth in emerging markets. Adapting its products to meet local regulatory requirements and market needs will be crucial for success.
- Development of new diagnostic assays: Sona Nanotech can leverage its gold nanorod technology to develop new diagnostic assays for a wider range of diseases. The market for point-of-care diagnostics is expanding rapidly, driven by the need for faster and more convenient testing. Focusing on areas such as infectious diseases and chronic conditions can create new revenue streams for the company.
- Licensing of its gold nanorod technology: Sona Nanotech can license its gold nanorod technology to other companies for use in their products. This can generate revenue and expand the reach of its technology without requiring significant investment. Identifying potential licensees in complementary industries, such as cosmetics and electronics, can create new opportunities for growth.
What Are SNANF's Competitive Advantages?
- Proprietary gold nanorod technology.
- Expertise in nanotechnology and its applications in diagnostics and therapeutics.
- Established manufacturing capabilities for gold nanorod products.
- Development of the Nanotech COVID-19 Lateral Flow Assay, providing a competitive advantage in the COVID-19 testing market.
What Does SNANF Do?
Sona Nanotech Inc., based in Halifax, Canada, is a nanotechnology life sciences company specializing in the development and manufacturing of gold nanorod products. The company's core technology revolves around the unique properties of gold nanorods, which are utilized in a variety of applications, including diagnostic tests, drug delivery, and cancer treatment. Sona Nanotech offers a range of products, including Gemini and Omni gold nanorods, designed for medical applications. A key product is the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay designed for the detection of the SARS-CoV-2 spike protein antigen in saliva specimens. The company's products cater to diverse sectors, including medical, consumer, military, and veterinary diagnostics. Beyond its product offerings, Sona Nanotech also provides contract services, leveraging its expertise in nanotechnology. The company aims to capitalize on the increasing demand for rapid and accurate diagnostic solutions, as well as innovative drug delivery systems. Sona Nanotech operates with a team of 8 employees, focusing on research, development, and commercialization of its nanotechnology-based solutions.
What Products and Services Does SNANF Offer?
- Manufactures gold nanorod products for diagnostic tests.
- Develops and sells the Nanotech COVID-19 Lateral Flow Assay for detecting SARS-CoV-2.
- Offers Gemini gold nanorods for medical applications.
- Provides Omni gold nanorods for medical applications.
- Offers contract services related to nanotechnology.
- Develops products for drug delivery applications.
- Creates solutions for cell imaging and cancer treatment.
How Does SNANF Make Money?
- Sells gold nanorod products to diagnostic test manufacturers.
- Generates revenue from sales of the Nanotech COVID-19 Lateral Flow Assay.
- Provides contract research and development services.
- Commercializes gold nanorods for various applications, including medical and veterinary diagnostics.
What Industry Does SNANF Operate In?
Sona Nanotech Inc. operates within the medical diagnostics and research industry, which is experiencing growth driven by technological advancements and increasing demand for personalized medicine. The market for nanotechnology in healthcare is expanding, with applications in diagnostics, drug delivery, and regenerative medicine. Sona Nanotech competes with established diagnostic companies and other nanotechnology firms. Key trends include the development of rapid and point-of-care diagnostics, as well as targeted drug delivery systems. The company's success depends on its ability to innovate and commercialize its gold nanorod technology effectively.
Who Are SNANF's Key Customers?
- Diagnostic test manufacturers.
- Hospitals and clinics using COVID-19 rapid tests.
- Research institutions and universities.
- Veterinary diagnostic laboratories.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
Sona Nanotech Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Halifax, CA. The company is led by CEO David Andrew Regan. SNANF has traded publicly since 2006.
Financial Health
Sona Nanotech Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -46.18 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -6.9%, the inverse of the P/E and a quick read on earnings relative to price.
SNANF Valuation & Market Position
With a $27.7M market cap, Sona Nanotech Inc. sits in the micro-cap segment of the market.
Earnings Track Record
Sona Nanotech Inc. has beaten Wall Street's EPS estimate in 5 of its last 5 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 41.5% above estimates on average.
Forward Outlook
Wall Street analysts project Sona Nanotech Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.06.
SNANF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary gold nanorod technology platform.
- Development of the Nanotech COVID-19 Lateral Flow Assay.
- Expertise in nanotechnology applications in diagnostics and therapeutics.
- Potential for expansion into new therapeutic areas.
Bear Case
- Small market capitalization and limited financial resources.
- Negative P/E ratio indicating lack of profitability.
- Dependence on a limited number of products and services.
- OTC market listing, potentially limiting investor access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SNANF Latest News
-
Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds
Yahoo! Finance: SNANF News · Aug 10, 2026
-
SONA NANOTECH TO ARRANGE PRIVATE PLACEMENT FINANCING
Yahoo! Finance: SNANF News · Jul 31, 2026
SNANF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SNANF.
Price Targets
Wall Street price target analysis for SNANF.
SNANF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SNANF; grades run from A+ (80-100) to F (below 30).
Leadership: David Andrew Regan
CEO
David Andrew Regan serves as the CEO of Sona Nanotech Inc. His background includes experience in managing and leading technology-focused companies. He is responsible for the overall strategic direction and operational execution of the company. His leadership is focused on driving the commercialization of Sona Nanotech's gold nanorod technology and expanding its market presence.
Track Record: Under David Andrew Regan's leadership, Sona Nanotech has focused on developing and commercializing its Nanotech COVID-19 Lateral Flow Assay. He has overseen the company's efforts to secure regulatory approvals and establish partnerships. Key milestones include expanding the company's product portfolio and increasing its visibility in the nanotechnology-driven healthcare sector.
SNANF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sona Nanotech Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting or may be undergoing restructuring or have regulatory issues. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies face fewer listing requirements, resulting in increased risk and potential for information asymmetry.
- OTC Tier: OTC Other
- Limited financial disclosure requirements on the OTC market.
- Lower liquidity and higher price volatility compared to major exchanges.
- Potential for limited regulatory oversight and increased risk of fraud.
- Dependence on the success of its Nanotech COVID-19 Lateral Flow Assay and gold nanorod technology.
- Competition from established diagnostic companies with greater resources.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive landscape and market position.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's business plan and growth strategy.
- Check for any regulatory issues or legal proceedings involving the company.
- Monitor news and press releases for any updates or developments.
- Development of the Nanotech COVID-19 Lateral Flow Assay.
- Focus on nanotechnology applications in diagnostics and therapeutics.
- Presence of a CEO and management team.
- Publicly traded stock, even on the OTC market.
- Company website and investor relations materials.
SNANF Healthcare Stock FAQ
Is SNANF a good stock?
Stock Expert AI does not rate SNANF buy, sell or hold. Sona Nanotech Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about SNANF stock?
As of 2026-03-16, there is no available analyst coverage or consensus on Sona Nanotech Inc. (SNANF) due to its small market capitalization and OTC listing.
What are the key factors to evaluate for SNANF?
Evaluate SNANF on fundamentals, analyst consensus, and risk factors. However, the company's negative P/E ratio of -11.46 indicates it is not currently profitable. Not financial advice.
How frequently does SNANF data refresh on this page?
SNANF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SNANF's recent stock price performance?
Sona Nanotech Inc. (SNANF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary gold nanorod technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SNANF overvalued or undervalued right now?
Sona Nanotech Inc. (SNANF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SNANF?
Yes, most major brokerages offer fractional shares of Sona Nanotech Inc. (SNANF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SNANF's earnings and financial reports?
Sona Nanotech Inc. (SNANF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SNANF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.